Definition of VAP and the influence of biofilms: A brief overview of an ICU problem
Review article
Keywords:
Pneumonia, Ventilator-Associated, Biofilm, Intensive Care Units, Bacterial Structure, Cross infectionAbstract
VAP is a common, if not the most frequent cross-infection among ICU patients; it is a disease with high morbidity and mortality, which has been exacerbated in the last quinquennium by antibiotic resistance, making the management of cases difficult, increasing the mortality rate and healthcare expenses (either by increased antibiotic consumption, hospital stay, biosafety equipment and consumption of medical supplies).
Resistance is increased due to the inappropriate use of antibiotics by both the healthcare and agricultural sectors, as well as the ability of bacterial cells to form biofilms. Biofilms are polymeric matrix structures formed by one or more bacterial species, which allow the survival of the microorganisms that constitute them on both organic and inorganic surfaces. This review article provides a brief analysis of the relationship between VAP and biofilms in the ICU.
References
Capa Carrillo D, Herrera Viniachi I, Zambrano M. Complicaciones graves de neumonía en lactante mayor, a propósito de un caso. Ciencia Ecuador. 2019;1(6): 1–4. https://doi.org/10.23936/rce.v1i6.7.
Grief SN, Loza JK. Guidelines for the Evaluation and Treatment of Pneumonia. Primary Care: Clinics in Office Practice. 2018;45(3): 485–503. https://doi.org/10.1016/j.pop.2018.04.001.
Hooven TA, Polin RA. Pneumonia. Seminars in Fetal and Neonatal Medicine. 2017;22(4): 206–213. https://doi.org/10.1016/j.siny.2017.03.002.
Julián-Jiménez A, Adán Valero I, Beteta López A, Cano Martín LM, Fernández Rodríguez O, Rubio Díaz R, et al. Recomendaciones para la atención del paciente con neumonía adquirida en la comunidad en los Servicios de Urgencias. Revista Espanola De Quimioterapia: Publicacion Oficial De La Sociedad Espanola De Quimioterapia. 2018;31(2): 186–202.
Loor Parada W, Farfán Cano HR, González González M. Neumonía bacteriana e inmunosupresión por VIH, una revisión breve. Ciencia Ecuador. 2019;1: 1–4. https://doi.org/10.23936/rce.v1i5.6.
Ávila-Choez A, Pineda R. Relación entre mortalidad y neumonía asociada al ventilador en la unidad de terapia intensiva. Ciencia Ecuador. 2021;3(1): 1–6. https://doi.org/10.23936/rce.v3i1.26.
Luo W, Xing R, Wang C. The effect of ventilator-associated pneumonia on the prognosis of intensive care unit patients within 90 days and 180 days. BMC Infectious Diseases. 2021;21(1): 684. https://doi.org/10.1186/s12879-021-06383-2.
Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Medicine. 2020;46(5): 888–906. https://doi.org/10.1007/s00134-020-05980-0.
Spalding MC, Cripps MW, Minshall CT. Ventilator-Associated Pneumonia. Critical Care Clinics. 2017;33(2): 277–292. https://doi.org/10.1016/j.ccc.2016.12.009.
Wicky PH, Niedermann MS, Timsit JF. Ventilator-associated pneumonia in the era of COVID-19 pandemic: How common and what is the impact? Critical Care. 2021;25(1): 153, s13054-021-03571-z. https://doi.org/10.1186/s13054-021-03571-z.
Wang G, Zhao G, Chao X, Xie L, Wang H. The Characteristic of Virulence, Biofilm and Antibiotic Resistance of Klebsiella pneumoniae. International Journal of Environmental Research and Public Health. 2020;17(17): 6278. https://doi.org/10.3390/ijerph17176278.
Wu H, Moser C, Wang HZ, Høiby N, Song ZJ. Strategies for combating bacterial biofilm infections. International Journal of Oral Science. 2015;7(1): 1–7. https://doi.org/10.1038/ijos.2014.65.
Alecrim RX, Taminato M, Belasco A, Longo MCB, Kusahara DM, Fram D. Strategies for preventing ventilator-associated pneumonia: an integrative review. Revista Brasileira de Enfermagem. 2019;72(2): 521–530. https://doi.org/10.1590/0034-7167-2018-0473.
Coppadoro A, Bellani G, Foti G. Non-Pharmacological Interventions to Prevent Ventilator-Associated Pneumonia: A Literature Review. Respiratory Care. 2019;64(12): 1586–1595. https://doi.org/10.4187/respcare.07127.
Cornistein W, Colque ÁM, Staneloni MI, Monserrat Lloria M, Lares M, González AL, et al. [Pneumonia associated with mechanical ventilation. Update and recommendations inter- Societies SADI-SATI]. Medicina. 2018;78(2): 99–106.
Kollef M, Burnham CA. Ventilator-Associated Pneumonia: The Role of Emerging Diagnostic Technologies. Seminars in Respiratory and Critical Care Medicine. 2017;38(03): 253–263. https://doi.org/10.1055/s-0037-1599224.
Modi AR, Kovacs CS. Hospital-acquired and ventilator-associated pneumonia: Diagnosis, management, and prevention. Cleveland Clinic Journal of Medicine. 2020;87(10): 633–639. https://doi.org/10.3949/ccjm.87a.19117.
Alecrim RX, Taminato M, Belasco A, Longo MCB, Kusahara DM, Fram D. Strategies for preventing ventilator-associated pneumonia: an integrative review. Revista Brasileira de Enfermagem. 2019;72(2): 521–530. https://doi.org/10.1590/0034-7167-2018-0473.
Huang Z, Wang YH, Zhu HZ, Andrianova EP, Jiang CY, Li D, et al. Cross Talk between Chemosensory Pathways That Modulate Chemotaxis and Biofilm Formation. Msadek T (ed.) mBio. 2019;10(1). https://doi.org/10.1128/mBio.02876-18.
Costerton JW, Stewart P, Greenberg EP. Bacterial Biofilms: A Common Cause of Persistent Infections. Science. 1999;284(5418): 1318–1322. https://doi.org/10.1126/science.284.5418.1318.
Flemming HC, Wingender J, Szewzyk U, Steinberg P, Rice SA, Kjelleberg S. Biofilms: an emergent form of bacterial life. Nature Reviews Microbiology. 2016;14(9): 563–575. https://doi.org/10.1038/nrmicro.2016.94.
Geesey GG, Richardson WT, Yeomans HG, Irvin RT, Costerton JW. Microscopic examination of natural sessile bacterial populations from an alpine stream. Canadian Journal of Microbiology. 1977;23(12): 1733–1736. https://doi.org/10.1139/m77-249.
Rumbaugh KP, Sauer K. Biofilm dispersion. Nature Reviews Microbiology. 2020;18(10): 571–586. https://doi.org/10.1038/s41579-020-0385-0.
Maurice NM, Bedi B, Sadikot RT. Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections. American Journal of Respiratory Cell and Molecular Biology. 2018;58(4): 428–439. https://doi.org/10.1165/rcmb.2017-0321TR.
Davey ME, O’toole GA. Microbial Biofilms: from Ecology to Molecular Genetics. Microbiology and Molecular Biology Reviews. 2000;64(4): 847–867. https://doi.org/10.1128/MMBR.64.4.847-867.2000.
Flemming HC, Wingender J. The biofilm matrix. Nature Reviews Microbiology. 2010;8(9): 623–633. https://doi.org/10.1038/nrmicro2415.
González MJ. Evaluación de la capacidad de Escherichia coli uropatogénica de aislamientos clínicos de formar biofilms y comunidades bacterianas intracelulares y la efectividad de diferentes antibióticos. [Tesis de Maestría] [Uruguay]: Universidad de la República (Uruguay), Facultad de Ciencias, PEDECIBA; 2018. https://hdl.handle.net/20.500.12008/23243
Jamal M, Ahmad W, Andleeb S, Jalil F, Imran M, Nawaz MA, et al. Bacterial biofilm and associated infections. Journal of the Chinese Medical Association. 2018;81(1): 7–11. https://doi.org/10.1016/j.jcma.2017.07.012.
Roy R, Tiwari M, Donelli G, Tiwari V. Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action. Virulence. 2018;9(1): 522–554. https://doi.org/10.1080/21505594.2017.1313372.
Tolker-Nielsen T. Pseudomonas aeruginosa biofilm infections: From molecular biofilm biology to new treatment possibilities. APMIS. 2014;122: 1–51. https://doi.org/10.1111/apm.12335.
Arulkumaran N, Routledge M, Schlebusch S, Lipman J, Conway Morris A. Antimicrobial-associated harm in critical care: a narrative review. Intensive Care Medicine. 2020;46(2): 225–235. https://doi.org/10.1007/s00134-020-05929-3.
Fernando SM, Tran A, Cheng W, Klompas M, Kyeremanteng K, Mehta S, et al. Diagnosis of ventilator-associated pneumonia in critically ill adult patients—a systematic review and meta-analysis. Intensive Care Medicine. 2020;46(6): 1170–1179. https://doi.org/10.1007/s00134-020-06036-z.
Fernández Olmos A, García de la Fuente C, Saéz Nieto JA, Valdezate Ramos S. 37. Metodos de identificación bacteriana en el laboratorio de microbiología. In: Cercenado E, Cantón R (eds.) Procedimientos en Microbiología Clínica - Recomendaciones de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. 1a ed. España: SEIMC - Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; 2010. p. 2–28. https://seimc.org/contenidos/documentoscientificos/procedimientosmicrobiologia/seimc-procedimientomicrobiologia37.pdf
Das S, Zhou D, Nichols WW, Townsend A, Newell P, Li J. Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia. European Journal of Clinical Pharmacology. 2020;76(3): 349–361. https://doi.org/10.1007/s00228-019-02804-z.
Jung YJ, Kim EJ, Choi YH. Aerosolized antibiotics in the treatment of hospital-acquired pneumonia/ventilator-associated pneumonia. The Korean Journal of Internal Medicine. 2022;37(1): 1–12. https://doi.org/10.3904/kjim.2021.277.
Rocha G, Soares P, Gonçalves A, Silva AI, Almeida D, Figueiredo S, et al. Respiratory Care for the Ventilated Neonate. Canadian Respiratory Journal. 2018;2018: 1–12. https://doi.org/10.1155/2018/7472964.
Sweeney DA, Kalil AC. Why don’t we have more inhaled antibiotics to treat ventilator-associated pneumonia? Clinical Microbiology and Infection. 2019;25(10): 1195–1199. https://doi.org/10.1016/j.cmi.2019.04.018.
Wong FJ, Dudney T, Dhand R. Aerosolized Antibiotics for Treatment of Pneumonia in Mechanically Ventilated Subjects. Respiratory Care. 2019;64(8): 962–979. https://doi.org/10.4187/respcare.07024.
Zaragoza R, Vidal-Cortés P, Aguilar G, Borges M, Diaz E, Ferrer R, et al. Update of the treatment of nosocomial pneumonia in the ICU. Critical Care. 2020;24(1): 383. https://doi.org/10.1186/s13054-020-03091-2.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Ciencia Ecuador
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is a human-readable summary of (and not a substitute for) the license.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
